Genesis Molecular AI uses artificial intelligence to speed up drug discovery for the pharmaceutical industry. It combines 3D spatial graph modeling and advanced molecular simulation to generate and evaluate potential drug candidates and to uncover novel protein targets. The platform translates complex molecular data into actionable candidates by representing molecules in 3D graphs and running simulations to predict how they bind to target proteins, helping partners identify promising therapies. The company differentiates itself by integrating 3D spatial graph modeling with detailed molecular simulations to explore untapped chemical space and novel targets, and by focusing on business-to-business partnerships with pharma and biotech companies. Its goal is to accelerate drug discovery for partners by delivering AI-generated candidates and enabling faster progression from target to therapy.
Company Size
51-200
Company Stage
Late Stage VC
Total Funding
$400.1M
Headquarters
San Mateo, California
Founded
2019
See people who can refer or advise you
Help us improve and share your feedback! Did you find this helpful?